Clinical Trial

Efficacy of Lactobacillus Rhamnosus LRa05 in Gestational Diabetes

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 30, 2025 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to comprehensively evaluate the multifaceted impacts of Lactobacillus rhamnosus LRa05 on patients with gestational diabetes. Initially, the study will investigate the effects of LRa05 on improving patients' blood glucose levels and gut microbiota. Additionally, the study will assess the impact of this strain on patients' blood lipid levels, inflammatory markers, and body mass index (BMI). Furthermore, the study will also focus on its effects on thyroid function, vaginal microbiota, and bile acid metabolism in patients with gestational diabetes.
Trial Details
NCT Number NCT06901791
Lead Sponsor Wecare Probiotics Co., Ltd.
Conditions GDM
Enrollment 80 participants
Start Date 2025-04-10
Primary Completion 2025-07-31 (estimated)
Study Completion 2026-03-10 (estimated)
Updated on ClinicalTrials.gov 2025-03-30